This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (88)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Renal Diseases, Other  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

A Cost-effectiveness Analysis

L. Ebony Boulware, MD, MPH; Bernard G. Jaar, MD, MPH; Michelle E. Tarver-Carr, MD, PhD; Frederick L. Brancati, MD, MHS; Neil R. Powe, MD, MPH, MBA

JAMA. 2003;290:3101-3114.

Context  Chronic kidney disease is a growing public health problem. Screening for early identification could improve health but could also lead to unnecessary harms and excess costs.

Objective  To assess the value of periodic, population-based dipstick screening for early detection of urine protein in adults with neither hypertension nor diabetes and in adults with hypertension.

Design, Setting, and Population  Cost-effectiveness analysis using a Markov decision analytic model to compare a strategy of annual screening with no screening (usual care) for proteinuria at age 50 years followed by treatment with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II-receptor blocker (ARB).

Main Outcome Measure  Cost per quality-adjusted life-year (QALY).

Results  For persons with neither hypertension nor diabetes, the cost-effectiveness ratio for screening vs no screening (usual care) was unfavorable ($282 818 per QALY; incremental cost of $616 and a gain of 0.0022 QALYs per person). However, screening such persons beginning at age 60 years yielded a more favorable ratio ($53 372 per QALY). For persons with hypertension, the ratio was highly favorable ($18 621 per QALY; incremental cost of $476 and a gain of 0.03 QALYs per person). Cost-effectiveness was mediated by both chronic kidney disease progression and death prevention benefits of ACE inhibitor and ARB therapy. Influential parameters that might make screening for the general population more cost-effective include a greater incidence of proteinuria, age at screening ($53 372 per QALY for persons beginning screening at age 60 years), or lower frequency of screening (every 10 years: $80 700 per QALY at age 50 years; $6195 per QALY at age 60 years; and $5486 per QALY at age 70 years).

Conclusions  Early detection of urine protein to slow progression of chronic kidney disease and decrease mortality is not cost-effective unless selectively directed toward high-risk groups (older persons and persons with hypertension) or conducted at an infrequent interval of 10 years.

Author Affiliations: Department of Medicine, Johns Hopkins University School of Medicine (Drs Boulware, Jaar, Brancati, and Powe), Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (Drs Boulware, Brancati, and Powe), Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions (Drs Boulware, Jaar, Tarver-Carr, Brancati, and Powe), Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Cost-effectiveness of Screening for Proteinuria
Ron T. Gansevoort, Paul E. de Jong, and Maarten J. Postma
JAMA. 2004;291(12):1442-1443.
EXTRACT | FULL TEXT  

Cost-effectiveness of Screening for Proteinuria—Reply
L. Ebony Boulware, Bernard G. Jaar, and Neil R. Powe
JAMA. 2004;291(12):1443.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chronic kidney disease and end-stage renal disease--a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'
Zoccali et al.
NDT Plus 2009;0:sfp127v1-sfp127.
ABSTRACT | FULL TEXT  

Community-based study on CKD subjects and the associated risk factors
Chen et al.
Nephrol Dial Transplant 2009;24:2117-2123.
ABSTRACT | FULL TEXT  

Are We Ready to Screen the General Population for Microalbuminuria?
Fried
J. Am. Soc. Nephrol. 2009;20:686-688.
FULL TEXT  

The Costs and Benefits of Automatic Estimated Glomerular Filtration Rate Reporting
den Hartog et al.
CJASN 2009;4:419-427.
ABSTRACT | FULL TEXT  

Measuring the Value of Public Health Systems: The Disconnect Between Health Economists and Public Health Practitioners
Neumann et al.
AJPH 2008;98:2173-2180.
ABSTRACT | FULL TEXT  

Screening for CKD with eGFR: Doubts and Dangers
Glassock and Winearls
CJASN 2008;3:1563-1568.
ABSTRACT | FULL TEXT  

Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria
Postma et al.
Nephrol Dial Transplant 2008;23:1103-1106.
FULL TEXT  

Fact or fiction of the epidemic of chronic kidney disease--let us not squabble about estimated GFR only, but also focus on albuminuria
de Jong and Gansevoort
Nephrol Dial Transplant 2008;23:1092-1095.
FULL TEXT  

Principles of Screening for Chronic Kidney Disease
Jaar et al.
CJASN 2008;3:601-609.
FULL TEXT  

Screening for Chronic Kidney Disease: Where Does Europe Go?
de Jong et al.
CJASN 2008;3:616-623.
ABSTRACT | FULL TEXT  

World Kidney Day 2008: Think Globally, Speak Locally
Davis et al.
J. Am. Soc. Nephrol. 2008;19:413-416.
FULL TEXT  

Kidney Disease Screening Program in Japan: History, Outcome, and Perspectives
Imai et al.
CJASN 2007;2:1360-1366.
ABSTRACT | FULL TEXT  

The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward
Kiberd
J. Am. Soc. Nephrol. 2006;17:2967-2973.
ABSTRACT | FULL TEXT  

Screening, Monitoring, and Treatment of Albuminuria: Public Health Perspectives
de Jong and Curhan
J. Am. Soc. Nephrol. 2006;17:2120-2126.
ABSTRACT | FULL TEXT  

Early Detection of Progressive Chronic Kidney Disease: Is It Feasible?
Gansevoort et al.
J. Am. Soc. Nephrol. 2006;17:1218-1220.
FULL TEXT  

Screening for renal disease--what can be learned from the Okinawa experience
Iseki
Nephrol Dial Transplant 2006;21:839-843.
FULL TEXT  

Epidemiology and costs of chronic obstructive pulmonary disease
Chapman et al.
Eur Respir J 2006;27:188-207.
FULL TEXT  

Use of Protein:Creatinine Ratio Measurements on Random Urine Samples for Prediction of Significant Proteinuria: A Systematic Review
Price et al.
Clin. Chem. 2005;51:1577-1586.
ABSTRACT | FULL TEXT  

Proteinuria: A Link to Understanding Changes in Vascular Compliance?
Bakris
Hypertension 2005;46:473-474.
FULL TEXT  

Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study
Arnlov et al.
Circulation 2005;112:969-975.
ABSTRACT | FULL TEXT  

Is Statistical Significance Always Significant?
Koretz
Nutr Clin Pract 2005;20:303-307.
ABSTRACT | FULL TEXT  

Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression
Wang et al.
Circulation 2005;111:1370-1376.
ABSTRACT | FULL TEXT  

Chronic Kidney Disease Predicts Cardiovascular Disease
Hostetter
NEJM 2004;351:1344-1346.
FULL TEXT  

Cost-effectiveness of Screening for Proteinuria
Gansevoort et al.
JAMA 2004;291:1442-1443.
FULL TEXT